Secretary Alex Azar

Secretary Alex Azar is a renowned American attorney, politician, and former United States Secretary of Health and Human Services, serving under the Donald Trump administration from 2018 to 2021. Azar's tenure was marked by significant events, including the COVID-19 pandemic, which posed substantial challenges to the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), and the Food and Drug Administration (FDA). His leadership was also influenced by collaborations with other cabinet members, such as Mike Pence, Steven Mnuchin, and Wilbur Ross. Azar's background in law and health policy, shaped by his experiences at Yale University, Yale Law School, and Kenyon College, played a crucial role in his decision-making as Secretary.

● Early Life and Education

Azar was born in Johnstown, Pennsylvania, and grew up in Madison, Indiana, where he developed an interest in politics and public service, inspired by figures like Ronald Reagan and Margaret Thatcher. He attended Park Tudor School in Indianapolis, Indiana, before enrolling at Yale University, where he studied economics and philosophy, and was influenced by the works of Milton Friedman and Friedrich Hayek. Azar later earned his Juris Doctor degree from Yale Law School, where he was a member of the Yale Law Journal and was influenced by the teachings of Guido Calabresi and Anthony Kronman. His educational background also included a stint at Kenyon College, where he studied English literature and was exposed to the works of William Shakespeare and Jane Austen.

● Career

Before entering public service, Azar worked as a law clerk for Judge Kenneth Starr of the United States Court of Appeals for the District of Columbia Circuit and later for Associate Justice Antonin Scalia of the Supreme Court of the United States. He then joined the law firm Wiley Rein LLP, where he worked alongside notable attorneys like Fred Fielding and Richard Wiley. Azar's career in the pharmaceutical industry began at Eli Lilly and Company, where he rose through the ranks to become the company's president of Lilly USA, working closely with executives like John Lechleiter and David Ricks. His experience in the private sector was also shaped by his involvement with organizations like the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO).

● Secretary of Health and Human Services

As Secretary of Health and Human Services, Azar played a crucial role in shaping the Trump administration's health care policies, including the Affordable Care Act (ACA) and the Medicare program. He worked closely with other administration officials, such as Seema Verma of the Centers for Medicare and Medicaid Services (CMS) and Scott Gottlieb of the Food and Drug Administration (FDA), to implement policies like the Right to Try Act and the Opioid Crisis Response Act. Azar's tenure was also marked by collaborations with Congress, including working with lawmakers like Mitch McConnell, Paul Ryan, and Nancy Pelosi to pass legislation like the 21st Century Cures Act.

● Policy Initiatives

Azar's policy initiatives as Secretary focused on issues like opioid addiction, mental health, and health care access, with a particular emphasis on rural health care and telemedicine. He launched initiatives like the HHS Opioid Strategy and the National Institutes of Health's (NIH) HEAL Initiative, which aimed to combat the opioid epidemic and improve treatment options for individuals struggling with addiction. Azar also worked to promote biosimilar drugs and generic drugs, aiming to increase competition and reduce prices in the pharmaceutical market, with support from organizations like the Generic Pharmaceutical Association (GPhA) and the Biosimilars Forum.

● Controversies and Criticism

Azar's tenure as Secretary was not without controversy, with critics arguing that his policies and actions were influenced by his background in the pharmaceutical industry, particularly his time at Eli Lilly and Company. Some lawmakers, including Elizabeth Warren and Bernie Sanders, raised concerns about potential conflicts of interest and the impact of his policies on health care costs and access to care. Azar also faced criticism for his handling of the COVID-19 pandemic, with some arguing that the Trump administration's response was inadequate and that Azar's leadership was insufficient, particularly in regards to the CDC's and FDA's roles in responding to the crisis.

● Later Life and Activities

After leaving office, Azar has remained involved in the health care sector, serving as a senior fellow at the American Enterprise Institute (AEI) and advising companies like Cerner Corporation and Optum. He has also been involved in various initiatives, including the National Academy of Medicine's (NAM) Action Collaborative on Countering the U.S. Opioid Epidemic and the Bipartisan Policy Center's (BPC) Health Innovation Initiative. Azar has continued to advocate for policies aimed at improving health care access and affordability, and has written extensively on topics like health care reform and pharmaceutical innovation, with his work published in outlets like The Wall Street Journal and Forbes.